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The production and use of pseudotyped viral particles is widely established for many viruses, and 12	
  
applications in the fields of serology and vaccine development are manifold. Viral pseudotypes have 13	
  
proven to be powerful tools to study the effects of viral evolution on serological outcomes, viral 14	
  
tropism and immunogenicity studies [1–7]. Pseudotyped viruses are chimeric constructs in which the 15	
  
outer (surface) glycoprotein(s) of one virus is combined with the replication-defective viral “core” of 16	
  
another virus [8, 9]. Pseudotypes allow for accurate, sequence-directed, sensitive antibody 17	
  
neutralization assays and antiviral screening to be conducted within a low biosecurity facility and offer 18	
  
a safe and efficient alternative to wildtype virus use [8].  19	
  
The protocol outlined here represents a rapid and reliable method for the generation of high-titre 20	
  
pseudotype viral particles with the MERS-CoV spike protein on a lentiviral core, and is adapted from 21	
  
previously published protocols [1, 7, 10]. This protocol is optimised for transfection in a 100mm petri 22	
  






This protocol has a number of advantages including. 26	
  
1. Use of readily available reagents  27	
  
2. Consistent, high virus titres 28	
  












• HEK 293T/17 cells (ATCC® CRL-11268™) 35	
  
• Dulbecco’s modified Eagle medium with Glutamax (Cat. No. 31966-021) Supplemented with 36	
  
10% Foetal bovine serum and 1% penicillin/Streptomycin (P/S) 37	
  
• Trypsin-EDTA (0.05%), phenol red (Cat. No. 25300-054) 38	
  
• Gibco Reduced Serum media Opti-MEM® (Cat. No. 31985-047) 39	
  
• Optional: TC20™ Automated Cell Counter (Cat. No. 145-0102EDU)  40	
  
• Branched Polyethyleneimine solution at concentration of 1mg/ml (Cat. No. 408727) 41	
  
• Sterile syringes (10ml) 42	
  
• Millex-HA 0.45 µm filters (Cat. No. SLHAM33SS) 43	
  
• Rabbit Polyclonal Antibody to Novel coronavirus (HCoV-EMC/2012) Spike protein 44	
  
(SinoBiological Cat. No. 40069-RP02)  45	
  
• Nunc® UpCell™ Surface cell culture dish (Manufacturer No. 174902) 46	
  












Glycoprotein expression plasmid: pCAGGS-MERS-CoV Spike (Note: The MERS-CoV Spike protein 53	
  
should be codon optimised) 54	
  
Lentiviral vector plasmid expressing firefly luciferase: pCSFLW [11]  55	
  












1. 293T/17 cells should be subcultured into 100mm petri dishes at a ratio that will yield 70-90% 62	
  
confluence at the time of transfection. In our hands this protocol yields similar results 63	
  








2. DMEM/10% FBS/1% P/S and Opti-MEM® should be pre-warmed to 37°C using a water bath or 68	
  
similar.   69	
  
3. Prepare and label two sterile 1.5ml microcentrifuge tubes (tube 1 and tube 2) per transfection.  70	
  
4. Add the following plasmids (0.9:1:1.5 envelope:core:vector ratio) for transfection to tube 1:  71	
  
a. pCAGGS-MERS-CoV spike: 0.9 µg 72	
  
b. p8.91-lentiviral vector: 1.0 µg 73	
  
c. pCSFLW: 1.5 µg 74	
  
5. Add 200μl Opti-MEM® to the plasmid DNA mix (tube 1). 75	
  
6. Add 200μl Opti-MEM® and 35 µl of 1mg/ml PEI to tube 2. 76	
  




8. After incubation, pipette the Opti-MEM®/PEI solution from tube 2 into the Opti-MEM®/DNA 79	
  
solution in tube 1. 80	
  




10. While transfection mix is incubating, the culture media on the 293T/17 cells should be removed 83	
  
and 7ml of fresh DMEM/10% FBS/1% P/S added. It is important at this point to add media 84	
  
slowly to one side of the dish to avoid detaching adherent cells.  85	
  
11. After 20 min incubation, pipette the DNA/Opti-MEM®/PEI solution onto the 293T/17 cells by 86	
  




12. Incubation Step. Incubate the plate at 37°C, 5% CO2 overnight (o/n). In our hands incubation 89	
  








13. Post o/n incubation the media on the cells should be changed and 7ml fresh DMEM/10% 94	
  
FBS/1% P/S added. Add media slowly to one side of the plate to avoid cell detachment.  95	
  








15. Supernatant containing the viral pseudotype particles are harvested using a 10ml sterile 100	
  
syringe and then filtered into falcon tubes via a syringe driven Millex HA-0.45µm filter. 101	
  
16. Store all filtered supernatant at -80°C. It is recommended that supernatant is stored as aliquots 102	
  
to avoid multiple freeze thaw cycles. Note: Supernatant may be stored at 4ºC for up to one 103	
  




17. Optional Step: Additional media may be added to cells to allow a second harvest 18-24 hours 106	
  
later by adding further DMEM/10% FBS/1% P/S. In this case extreme care must taken in initial 107	
  
pseudotype collection (step 15) to avoid damage to cell monolayer. We have observed that 108	
  






Note: A control pseudotype virus may be created by following the steps outlined above but leaving 111	
  
out the pCAGGS-MERS-CoV spike construct. This produces particles that do not express the viral 112	
  
surface glycoprotein and therefore should be unable to transduce target cells (∆-env control).   113	
  
Titration Steps (Figure 1) 114	
  
Note: Titration consists of transduction of reporter (in this case firefly luciferase) into target 115	
  
cells mediated by the viral glycoprotein expressed on the viral pseudotype. Controls for 116	
  
titrations are provided via the inclusion of “cell only” and “∆-env” columns. 117	
  
1. In a 96 well white plate add 50 µl of DMEM/10% FBS/1% P/S to the entire column of “cell 118	
  
only” control (see Figure 1 column 12). 119	
  
2. Add 50 µl of DMEM/10% FBS/1% P/S from row B to H that are to contain pseudotyped virus 120	
  
or ∆-env control.  121	
  
3. Add 100 µl of MERS pseudotype virus supernatant to each well of row A (excluding control 122	
  
columns) and add 100ul of ∆-env to column 11 (See Figure 1). 123	
  







Figure 1: Serial dilution step showing addition of 100ul of pseudotype virus supernatant to each well 127	
  
of row A and dilution of 50ul taken from this well to row B. This process is continued to end of plate 128	
  
(row H) at which point the final 50ul is discarded. ∆-env control is indicated in red (column 11) and cell 129	
  
only control is indicated in green (column 12).  130	
  
5. With each dilution step use pipette to mix 8 times up and down. 131	
  
6. After completing serial dilution the final 50 µl from the last well of each column should be 132	
  
discarded. Note: at this point each well should contain 50µl of mixed DMEM and viral 133	
  
supernatant.   134	
  




a. Remove media from plate 137	
  
b. Wash the plate with 2 ml of trypsin and discard trypsin 138	
  
c. Add additional 2 ml of trypsin to the plate to detach cells 139	
  




e. Count cells using TC20™ Automated Cell Counter or haemocytometer and add 1x104 142	
  
cells in a total volume of 50 µl to each well 143	
  
8. Centrifuge plate for 1 minute at 500rpm if there are droplets on the sides of the wells  144	
  
9. Incubate the plate for 48 hours at 37°C 5% CO2 145	
  






Method validation and transfection results  149	
  
Figure 2 displays data recorded from multiple transfections indicating consistency of results. Results 150	
  
are measured in Relative Luminescence Units (RLUs) as measured using a GloMax® 96 Microplate 151	
  
Luminometer and the Bright Glo™ luciferase assay system. The pseudotype particles generated in 152	
  
the absence of viral envelope (Delta) show increased luciferase activity compared to cell only in part 153	
  
due to transformation method used to discern RLU per ML. The presence of some carry-over 154	
  















































Figure 2: Pseudotype production titres from three replicates of optimised transfection protocol using codon optimised MERS-157	
  
CoV Spike.  158	
  
Figure 3 shows percentage neutralization of the MERS-CoV pseudotype with commercially produced 159	
  
anti-MERS spike antibody. Figure clearly indicates that as the dilution factor increases, so the 160	
  
percentage neutralization decreases, 100% neutralization indicates that RLU values at this 161	
  
concentration are equivalent to a delta envelope control.  162	
  



















Figure 3: Anti-MERS-Spike Antibody (Rabbit Polyclonal Antibody to Novel coronavirus (HCoV-EMC/2012) Spike protein) 164	
  











  Transfection 1  Transfection 2 Transfection 3 Cell Only 
Mean/ml Titre 2.2E+08 2.3E+08 2.6E+08 91 
Table 1: Mean RLU calculated per ml of viral supernatant for three pseudotype production runs. The protocol outlined here 169	
  
provides a rapid and consistent method for the generation of high-titre viral pseudotype particles expressing the MERS-CoV 170	
  
spike protein suitable for further downstream applications. Efficient knock-down of pseudotype virus entry using a polyclonal 171	
  
antibody directed against the spike glycoprotein (Figure 3) demonstrates potential utility for vaccine immunogenicity and 172	
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